A professor at the University at Buffalo School of Medicine and Biomedical Sciences, he began his Roswell career as Vice President for Clinical Research in 2002 and was elevated to the cancer institute's top post in 2007. He shepherded the institute through a variety of changes, and recently presided over RPCI's renewal process that once again designated the facility as a National Cancer Institute's comprehensive cancer center.
"During the course of his leadership, Dr. Trump has done a truly remarkable job of keeping the Institute on course with the strategic plan," said Roswell Park Cancer Institute Board Chairman Michael Joseph in a prepared statement (below)
"...We will embark on a national search for his replacement, and we are confident that Dr. Trump has paved the way for Roswell Park Cancer Institute to continue to succeed," Joseph said.
Trump is a practicing oncologist working with prostate cancer and other urologic cancer patients. He holds several patents related to the use of Vitamin D in chemotherapy, and headed the Institute’s clinical research program in vitamin D-based cancer prevention and treatment, while also being responsible for the institute's day-to-day operations.
Here's the announcement from Michael Joseph, Chair of Roswell's Board of Directors
After more than seven years serving as President and CEO of Roswell Park Cancer Institute (RPCI), Dr. Donald Trump has announced his well-deserved retirement, effective Dec. 31, 2014.
During the course of his leadership, Dr. Trump has done a truly remarkable job of keeping the Institute on course with the strategic plan, further ensuring its mission is aligned and integrated throughout the Institute. RPCI has grown in cancer care, education and research at a time when economics of health care have never been more challenging.
Roswell Park’s clinical revenues and its unique patient care programs continue to increase as Dr. Trump has been at the forefront of a “transformation process” at the Institute. Further, he led several important initiatives that have great potential to enhance collaborative relationships with local and regional health care partners, thus benefiting cancer patients not only at Roswell Park, but in Upstate NY.
In addition to his role as President and CEO, Dr. Trump also contributed immensely to patient care and research. He led the Institute’s strong clinical research program in vitamin D-based cancer prevention and treatment, and cared for patients with prostate cancer and other urologic cancers. The timing of his decision to retire is apt, following the successful renewal of National Cancer Institute’s Cancer Center Support Grant (CCSG), which the Institute announced on July 1.
We will embark on a national search for his replacement, and we are confident that Dr. Trump has paved the way for Roswell Park Cancer Institute to continue to succeed.
The Board of Directors wish Dr. Trump much happiness on his retirement, and thank him for his years of leadership and dedication to the Institute, Western New York Region and patients and families whose lives he has touched.